3-[(heptan-2-yl)carbamoyl]-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid

Compound number
MolPort-001-569-520
IUPAC
3-[(heptan-2-yl)carbamoyl]-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
IUPAC traditional
3-[(heptan-2-yl)carbamoyl]-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
SMILES
CCCCCC(C)NC(=O)C1C2CCC(O2)C1C(O)=O
InChI key
NLROVRSIEBLLOY-UHFFFAOYSA-N
Molecular formula
Molecular weight
283.368
Solubility
not available

Marketplace Offers

Vitas M Chemical Limited

Direct S&H to USA:
220.00 USD
Catalog
Screening compound
Ships out
15 business days
Purity
>90%
Last updated
this week
In warehouse
14.00 mg

Supplier Catalogue Data

Pack size Ships out Price Quantity
1 mg September 9, 2022 30.22 USD
Add to Cart Buy
2 mg September 9, 2022 31.93 USD
Add to Cart Buy
3 micromol September 9, 2022 30.00 USD
Add to Cart Buy

Get your compounds in the right format

Molport Reweighting and Reformatting Services

More Information

Compound identifiers

Compound number
MolPort-001-569-520

Names, Synonyms and 3rd Party Identifiers

Name
3-(1-Methyl-hexylcarbamoyl)-7-oxa-bicyclo[2.2.1]heptane-2-carboxylic acid
3-(heptan-2-ylcarbamoyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
3-[N-(methylhexyl)carbamoyl]-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
3-{(-methylhexyl)aminocarbonyl}-7-oxabicyclo2.2.heptane-2-carboxylic acid
3-{[(1-methylhexyl)amino]carbonyl}-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
MFCD03759318

InChI

InChI
1/C15H25NO4/c1-3-4-5-6-9(2)16-14(17)12-10-7-8-11(20-10)13(12)15(18)19/h9-13H,3-8H2,1-2H3,(H,16,17)(H,18,19)
InChI key
NLROVRSIEBLLOY-UHFFFAOYSA-N

Formula

Molecular formula
C15H25NO4
Molecular weight
283.368

Molport Guarantee

When you purchase products through the Molport website from any seller other than Molport itself, you will be protected by the Molport Guarantee. If you purchase products from Molport itself, this Molport Guarantee will not apply, and your remedies will be governed by the Molport Terms of Sale and Supply.

We use cookies to improve your experience on our websites and for advertising. By clicking "Accept All", you consent to our use of cookies. Learn more.

Feedback